Abstract
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-27 |
| Number of pages | 5 |
| Journal | Current Osteoporosis Reports |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2010 |
Keywords
- BMD
- BMP
- Osteoporosis
- PTH
- Sclerostin
- Wnt
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism